TNFRSF10B and ovarian cancer: We hypothesised that by selectively targeting DR5 on ovarian cancer cell surfaces, using a potent and specific TRAIL variant with higher binding affinity than WT TRAIL [39,47], we can avoid competition with other death receptors, especially decoy receptors, and exert a greater cytotoxic.